drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular therapy (CAR T cells)
drug_description
Autologous, lentiviral-transduced PSMA-directed CAR T-cell therapy with a humanized J591-derived anti-PSMA scFv, CD2 costimulatory domain, and dual armoring via a dominant-negative TGFβ receptor and a PD1.CD28 switch receptor.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express a PSMA-specific CAR (humanized J591 scFv) with a CD2 costimulatory domain. The cells are dually armored with a dominant-negative TGF-beta receptor to resist TGF-beta–mediated immunosuppression and a PD1.CD28 switch receptor that converts PD-1 inhibitory signals into CD28 costimulation, enhancing activation, persistence, and cytotoxic killing of PSMA-expressing tumor cells.
drug_name
TmPSMA-02 CAR T Cells
nct_id_drug_ref
NCT06046040